Orally Available Superoxide Dismutase Prevents Tumor Progression in Mice
Author Information
Author(s): Fumio Okada, Hiroshi Shionoya, Masahiro Kobayashi, Toshiyuki Kobayashi, Hiroshi Tazawa, Kei Onuma, Yoshihiro Iuchi, Nobuyuki Matsubara, Toshihiro Ijichi, Benoit Dugas, Masahiro Hosokawa
Primary Institution: Yamagata University
Hypothesis
Can an orally available superoxide dismutase prevent inflammation-mediated tumor progression in benign mouse fibrosarcoma cells?
Conclusion
The study found that the superoxide dismutase derivative, oxykine, reduced tumor growth and prevented the acquisition of metastatic properties in fibrosarcoma cells.
Supporting Evidence
- Oxykine treatment resulted in a lower tumor incidence compared to control groups.
- Histological examination showed less oxidative damage in oxykine-treated tumors.
- Oral administration of oxykine was necessary for its effectiveness.
- Significant increase in Mn-SOD activity was observed in tumor tissues from oxykine-treated mice.
- Metastatic incidence was significantly lower in mice treated with oxykine.
Takeaway
Giving mice a special medicine called oxykine helped stop some cancer cells from growing and spreading.
Methodology
Mice were treated with oxykine or control substances before and after tumor cell implantation, and tumor growth and metastasis were measured.
Potential Biases
Potential bias in the selection of treatment groups and the assessment of outcomes.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
Female C57BL/6 mice, 5 weeks old.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website